Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER vs AFEDITAB CR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It causes vasodilation and decreases systemic vascular resistance.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
Short-term treatment of hypertension when oral therapy is not feasible or desirable,Management of severe hypertension (off-label)
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Intravenous infusion: initial dose 5 mg/hour, titrate by 2.5-5 mg/hour every 15-30 minutes as needed; maximum 15 mg/hour. Oral: 20 mg three times daily initially, then 30-40 mg three times daily.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
2 to 4 hours in healthy subjects; increased in hepatic impairment (up to 7 hours) and in elderly. No significant change in renal impairment.
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
Extensively metabolized in the liver via cytochrome P450 (CYP) enzymes, primarily CYP3A4 and CYP2C8, to inactive metabolites.
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Primarily hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion of metabolites accounts for approximately 60-70% of total elimination, with renal excretion of metabolites approximately 30-40%.
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
>95% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein).
92-98% bound to plasma proteins (primarily albumin)
8.4 L/kg (0.084 L/kg for a 70 kg adult? Please check: typical Vd is 8.4 L/kg? Actually nicardipine Vd is about 8.4 L/kg, which is large, indicating extensive tissue distribution). Correct: Vd = 8.4 L/kg (range 0.6-8.4 L/kg? Standard value is ~8.4 L/kg).
0.5-0.9 L/kg; high distribution indicates extensive tissue binding
Oral: 35% (extensive first-pass metabolism); intravenous: 100%.
Oral extended-release: approximately 50-60% due to first-pass metabolism; absolute bioavailability is 45-60%
Cr Cl 30-50 m L/min: maximum IV infusion rate 8 mg/hour; Cr Cl <30 m L/min: maximum IV infusion rate 5 mg/hour. Oral: no adjustment specified but monitor closely.
No adjustment required for any degree of renal impairment, but use with caution in patients with severe renal failure due to risk of hypotension.
Child-Pugh Class A: start with 50% of usual dose; Class B: start with 25% of usual dose; Class C: avoid use or use extreme caution.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Limited data; for IV infusion, start at 0.5 mcg/kg/min and titrate to effect; typical range 0.5-5 mcg/kg/min. Oral: 0.5-1 mg/kg/dose three times daily (max 30 mg/dose).
Not recommended for use in pediatric patients; safety and efficacy not established.
Start at lower end of dosing range; IV infusion initial rate 3 mg/hour; oral initial dose 20 mg twice daily; monitor blood pressure closely.
Initiate at lower end of dosing range (30 mg once daily) due to increased sensitivity to hypotensive effects and potential for reduced hepatic clearance.
None
No FDA black box warning.
Use caution in patients with coronary artery disease due to risk of increased angina or myocardial infarction,May cause hypotension, hepatic impairment, and elevated liver enzymes,May exacerbate congestive heart failure,Use with caution in patients with impaired renal function,Monitor blood pressure and heart rate during infusion
Hypotension, especially with immediate-release formulations,Peripheral edema,Hepatic impairment,Increased angina/acute MI upon withdrawal or dose escalation,Beta-blocker withdrawal,Congestive heart failure
Hypersensitivity to nicardipine or any component of the formulation,Advanced aortic stenosis (may reduce coronary perfusion),Lactation (use not recommended)
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concomitant use with strong CYP3A4 inducers (e.g., rifampin),Kock pouch (ileostomy)
Grapefruit and grapefruit juice may increase nicardipine levels; avoid concurrent use. No other significant food interactions. Maintain a heart-healthy, low-sodium diet as recommended for hypertension management.
Grapefruit juice increases nifedipine levels via CYP3A4 inhibition; avoid consumption. High-fat meals may delay absorption but do not alter overall exposure. Avoid alcohol as it can exacerbate vasodilation and hypotension.
NICARDIPINE (CARDENE) is a calcium channel blocker. Animal studies (rats, rabbits) showed embryotoxicity, fetotoxicity, and teratogenicity at doses ≥10× human dose. In humans, no adequate controlled studies; first trimester: potential for teratogenic risk (class C). Second and third trimesters: may cause fetal hypoxia, metabolic acidosis, and hypotension due to maternal hypotension. Use only if benefit outweighs risk.
Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine growth restriction (IUGR), and oligohydramnios; may cause neonatal hypotension, bradycardia, and hypoglycemia if used near term. Contraindicated in pregnancy for hypertension; use only if benefit outweighs risk (e.g., tocolysis).
NICARDIPINE is excreted in human milk. M/P ratio not reported. Limited data suggest low concentrations; however, potential for adverse effects in infant. Caution advised; consider alternative if possible.
Nifedipine excreted into breast milk; M/P ratio approximately 0.42-0.77; limited human data; no adverse effects reported in infants; use with caution during breastfeeding.
No specific dose adjustment guidelines for pregnancy; however, increased clearance and volume of distribution in pregnancy may necessitate higher doses. Start with lowest effective dose; titrate carefully to avoid maternal hypotension and fetal distress.
Plasma clearance may increase due to higher volume of distribution and metabolism; no specific dose adjustment recommended; titrate based on maternal blood pressure and response; avoid around labor due to tocolytic effect.
Cardene (nicardipine) IV infusion in D5W is a dihydropyridine calcium channel blocker used for short-term treatment of hypertension when oral therapy is not feasible. It is photosensitive; protect from light. Administer via central line due to peripheral vein irritation. Titrate based on blood pressure response; onset within minutes. Use with caution in patients with severe aortic stenosis, heart failure, or hepatic impairment. Avoid in patients with advanced aortic stenosis due to risk of reducing coronary perfusion.
AFEDITAB CR is a controlled-release formulation of nifedipine, a dihydropyridine calcium channel blocker. Avoid grapefruit juice as it inhibits CYP3A4 metabolism, increasing nifedipine levels. Use cautiously in patients with aortic stenosis or left ventricular dysfunction due to risk of hypotension. Do not crush or chew tablets; intact shell may appear in stool.
This medication is given intravenously to lower blood pressure quickly.,Your blood pressure and heart rate will be monitored closely during infusion.,Report any pain, redness, or swelling at the IV site immediately.,Avoid sudden position changes to prevent dizziness or fainting.,Do not stop the infusion without medical guidance.,Inform your healthcare provider if you have liver disease, heart failure, or aortic stenosis.
Swallow the tablet whole; do not crush, chew, or break it.,Avoid grapefruit juice while taking this medication.,Do not discontinue abruptly; taper under medical supervision.,Report symptoms of hypotension like dizziness or fainting.,Limit alcohol intake as it may worsen side effects.,Monitor for fluid retention (ankle swelling) and notify doctor if worsening.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER vs AFEDITAB CR, answered by our medical review team.
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER is a Calcium Channel Blocker that works by Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It causes vasodilation and decreases systemic vascular resistance.. AFEDITAB CR is a Calcium Channel Blocker that works by Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER and AFEDITAB CR depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER is: Intravenous infusion: initial dose 5 mg/hour, titrate by 2.5-5 mg/hour every 15-30 minutes as needed; maximum 15 mg/hour. Oral: 20 mg three times daily initially, then 30-40 mg three times daily.. The standard adult dose of AFEDITAB CR is: 30-60 mg orally once daily, extended-release; maximum 90 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER and AFEDITAB CR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER is classified as Category C. NICARDIPINE (CARDENE) is a calcium channel blocker. Animal studies (rats, rabbits) showed embryotoxicity, fetotoxicity, and teratogenicity at doses ≥10× human dose. In humans, no a. AFEDITAB CR is classified as Category C. Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine gro. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.